Develogen Aktiengesellschaft
Records under this name other than patents Develogen Aktiengesellschaft holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Develogen Aktiengesellschaft
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,943,357 | Crystallographic Structure of MNK-1 and MNK-2 Proteins Formerly held Term ended Term ended Oct 29, 2026 · Medium confidence | Term ended | Term ended Oct 29, 2026 | Medium confidence |
| US 8,697,713 | Pyrrolopyrimidines for Pharmaceutical Compositions Formerly held Lapsed on the fee record Ended Apr 15, 2026 · High confidence | Lapsed on the fee record | Ended Apr 15, 2026 | High confidence |
| US 8,129,164 | Crystallographic Structure of MNK-1 and MNK-2 Proteins Formerly held Term ended Term ended Mar 8, 2026 · Medium confidence | Term ended | Term ended Mar 8, 2026 | Medium confidence |
| US 9,029,323 | Neurturin conjugates for pharmaceutical use Formerly held Lapsed on the fee record Ended May 12, 2023 · USPTO record | Lapsed on the fee record | Ended May 12, 2023 | USPTO record |
| US 8,071,607 | MNK1 or MNK2 Inhibitors Formerly held Lapsed on the fee record Ended Dec 6, 2019 · High confidence | Lapsed on the fee record | Ended Dec 6, 2019 | High confidence |
| US 9,049,849 | Screening Methods for Compounds Useful for Treating Pancreatic Dysfunction Formerly held Lapsed on the fee record Ended Jun 9, 2019 · High confidence | Lapsed on the fee record | Ended Jun 9, 2019 | High confidence |
| US 8,828,934 | Mnk KINASE HOMOLOGOUS PROTEINS INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANELLE METABOLISM Formerly held Lapsed on the fee record Ended Sep 9, 2018 · Medium confidence | Lapsed on the fee record | Ended Sep 9, 2018 | Medium confidence |
| US 8,772,233 | Method for promoting regeneration of pancreatic beta-cells by administering neurturin Formerly held Lapsed on the fee record Ended Jul 8, 2018 · USPTO record | Lapsed on the fee record | Ended Jul 8, 2018 | USPTO record |
| US 8,633,201 | Thienopyrimidines Having MNK1/MNK2 Inhibiting Activity for Pharmaceutical Compositions Formerly held Lapsed on the fee record Ended Jan 21, 2018 · High confidence | Lapsed on the fee record | Ended Jan 21, 2018 | High confidence |
| US 8,501,473 | Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome Formerly held Lapsed on the fee record Ended Aug 6, 2017 · USPTO record | Lapsed on the fee record | Ended Aug 6, 2017 | USPTO record |